ľֱ

FDA OKs Anxiety Stimulation Device; Long-Term KarXT Data; Psilocybin Adverse Events

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

The FDA , a non-invasive electrical stimulation device used to treat generalized anxiety disorder, said maker Neurovalens.

were 30% less likely to acquire a driver's license than those without. They also had significantly higher rate of crashes, moving violations, and license suspensions. (JAMA Network Open)

Investigational xanomeline-trospium (KarXT) for schizophrenia showed without , Bristol Myers Squibb announced. At the 1-year mark, over 75% of patients achieved at least a 30% improvement in symptoms from baseline.

It's been 50 years since the that homosexuality should no longer be considered a mental illness. (NBC News)

First-degree relatives of individuals with had more than a ninefold higher risk for also developing such depression, according to a study of Taiwanese families. (JAMA Psychiatry)

A European Medicine Agency committee will meet this week to discuss . (Reuters)

Five adverse events -- headache, nausea, anxiety, dizziness, and elevated blood pressure -- were commonly reported across studies testing a , though most were tolerable and resolved within 2 days. (JAMA Network Open)

One man described how his dog helps him cope with like self-harm and hallucinations. (USA Today)

In recent years, more and more for their anxiety. (STAT)

The may be at the lowest it's been in decades, the director of the National Institute on Drug Abuse told the New York Times.

As has boomed, so have calls to gambling addiction hotlines. (NBC News)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.